Abstract
Endocrine therapy is an essential component in the curative treatment of hormone receptor (HR)-positive breast cancer. To improve treatment efficacy, the addition of metronomic chemotherapy has been tested and shown to improve therapeutic effects. To better understand cellular reactions to metronomic chemoendocrine therapy, we studied autophagy-related markers, beclin 1 and LC3, and apoptosis-related markers, TUNEL and M30, in pre- and post-treatment cancer tissues from a multicenter neoadjuvant trial, JBCRG-07, in which oral cyclophosphamide plus letrozole were administered to postmenopausal patients with HR-positive breast cancer. Changes in the levels of markers were compared with those following neoadjuvant endocrine therapy according to clinical response. Apoptosis, in addition to autophagy-related markers, increased following metronomic chemoendocrine therapy and such increases were associated with clinical response. By contrast, following endocrine therapy, the levels of apoptosis-related markers did not increase regardless of clinical response, whereas the levels of autophagy-related markers increased. Furthermore, levels of the apoptosis-related marker, M30, decreased in responders of endocrine therapy, suggesting that...Continue Reading
References
Mar 26, 1998·British Journal of Cancer·H J van SlootenJ H van Dierendonck
May 22, 1998·Breast Cancer Research and Treatment·P A EllisM Dowsett
Mar 25, 2000·Endocrine-related Cancer·P Lipponen
Jan 21, 2003·The Journal of Pathology·W Rachel DuanEric A G Blomme
Mar 5, 2004·Cancer Research·Gero KramerStig Linder
Mar 2, 2006·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·T UenoS Linder
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alberto BottiniAlfredo Berruti
Apr 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaHope S Rugo
Jan 15, 2011·Cancer Science·Masakazu ToiHironobu Sasano
Aug 23, 2011·The Breast : Official Journal of the European Society of Mastology·Masahiro TakadaMasakazu Toi
Aug 30, 2011·Cancer Chemotherapy and Pharmacology·Zhonghua WangXichun Hu
Feb 9, 2012·Onkologie·Peter BojkoWolfgang Abenhardt
Apr 25, 2012·Cancer Chemotherapy and Pharmacology·Masataka YoshimotoJunichi Sakamoto
May 9, 2012·Methods in Molecular Biology·Kateryna KyrylkovaChrissa Kioussi
Aug 23, 2012·PloS One·Cristina AmaralNatércia Teixeira
Dec 12, 2012·Lancet·Christina DaviesUNKNOWN Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group
Jan 16, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Cristina AmaralNatércia Teixeira
Oct 9, 2013·International Journal of Clinical Oncology·Takayuki UenoMasakazu Toi
Jan 28, 2014·Molecular Cell·Vladimir RogovVladimir Kirkin
May 20, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yuyu HeHonglei Chen
Jun 11, 2014·Nature Reviews. Clinical Oncology·Nicolas AndréEddy Pasquier
Jul 8, 2015·European Journal of Histochemistry : EJH·A M SchläfliM P Tschan
Mar 18, 2016·BMC Cancer·Takayuki UenoMasakazu Toi
Jul 19, 2017·Trends in Cancer·Nicolas AndréEddy Pasquier
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Nov 22, 2017·Endocrine-related Cancer·Louis W C ChowMasakazu Toi
Mar 14, 2018·ESMO Open·Takayuki UenoMasakazu Toi
May 8, 2018·Cancer Medicine·Takayuki UenoMasakazu Toi
Jun 16, 2018·Cancer Medicine·Nobuaki SatoMasakazu Toi
Citations
Jul 13, 2019·International Journal of Molecular Sciences·Veronica CocettaMonica Montopoli
Sep 29, 2019·Pharmaceuticals·Claudia RiccardiDaniela Montesarchio
Jan 24, 2020·Cell Death & Disease·Mingli HanHuaying Dong
Aug 28, 2020·Cancers·George TzanakakisDragana Nikitovic
Jun 3, 2021·Cancers·Marina Elena CazzanigaMaria Grazia Cerrito
Sep 28, 2021·Food & Function·Yujia ZhouShaoping Nie
Aug 1, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mingli HanHuaying Dong